News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Moderna stock shed 7% on Wednesday with no company news to blame, reopening a brutal question that its 439% year-to-date rally had been drowning out: what exactly does a $59 billion valuation buy on a revenue base this thin?
Moderna stock rallies as Wolfe Research upgrades it to "Peer Perform." But is there any further upside left in MRNA shares? Let’s find out!
RBC Capital Markets analyst Trung Huynh downgrades shares of the Keytruda maker following a nearly 13% rally.
RBC Capital noted that while the cancer vaccine results exceeded expectations, the stock’s $150 valuation is ‘unprecedented’ for a company facing a major loss of exclusivity in two years.
Investing.com -- Bank of America upgraded Moderna to Neutral with a $170 price objective, following a sharp rally in the stock after positive data on its personalized cancer vaccine, intismeran, in adjuvant melanoma.
Moderna, Inc. (NASDAQ:MRNA) is one of the 10 Best Performing American Stocks in June 2026. On July 7, 2026, RBC Capital raised the firm’s price target on Moderna, Inc. (NASDAQ:MRNA) to $45 from $38 and kept a Sector Perform rating on the shares as part of a broader Q2 earnings preview for biotech. RBC said […]
When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.